… Inhibition of CK1α sensitizes del(5q) MDS cells to lenalidomide. CK1α mediates also …
Though, inhibition of CK1α is a potential novel therapy not only in del(5q) MDS but also in MM. …

… In del(5q) MDS, IKZF1 degradation leads to activation of a RUNX1/… Lenalidomide-induced
CK1α degradation triggers specific death of the differentiating cell. Lenalidomide-induced cell …

… In summary, it appears that both CRBN-mediated degradation of CK1α and IKZF1 are
cooperative mechanisms explaining the lenalidomide-mediated induction of apoptosis in 5q-MDS …

… Thus, this work revealed novel targetable dependencies in LEN-resistant del(5q) MDS. …
IKZF1 degradation. Subsequent cell death occurs due to degradation of CK1α for which del(5q) …

… syndrome (MDS) with deletion of the long arm of the chromosome 5 (5q - syndrome, del( 5q))
can … 5q - syndrome belongs to low - risk MDS, which means low risk to transform to acute …

… lenalidomide-mediated degradation of CK1α. Mechanistic studies reveal that CRBN directly
binds CK1α, indicating that CK1α … of CK1α but not IKZF1 blunts the sensitivity of del(5q) MDS …

… of CK1α sensitizes del (5q) MDS cells to lenalidomide. … of CK1α is a potential novel therapy
not only in del (5q) MDS but … patients who have the deletion 5q chromosomal abnormality …

… to lenalidomide resistance in del(5q) MDS patients [19]. In addition, CRBN is required for the
degradation of CK1α and the activity of lenalidomide. … of resistance for del(5q) MDS cells. …

… of CK1α degradation in del(5q) MDS, we pursued the high-affinity complex of CRL4 CRBN
, CK1α and lenalidomide … ∆BPB –CRBN–lenalidomide–CK1α complex and its structure was …

… selectively ubiquitinated to undergo proteosomal degradation. In del(5q) MDS,
lenalidomide-bound cereblon selectively binds and degrades casein kinase 1A1 (CK1α), a member …